Cyclo Therapeutics, Inc. (CYTH) Prices 2.5M Unit Offering at $5/Unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Medifast launches Trilivy, replacing its Optavia brand
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
December 9, 2020 12:52 PM ESTTransaction Includes Uplisting to Nasdaq and Reverse Stock Split
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Cyclo Therapeutics or the Company) (NasdaqCM: CYTH) (NasdaqCM: CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo) in the treatment of Niemann-Pick Disease Type C (NPC), today announced the pricing of its underwritten public offering of 2,500,000 units at a price to the public of $5.00 per unit. Each unit issued in the offering consists of... More
